Futility Assessment of Recombinant Factor VII Activated for the Treatment of Hemorrhagic Shock Requiring Massive Transfusion.

@article{McMillen2013FutilityAO,
  title={Futility Assessment of Recombinant Factor VII Activated for the Treatment of Hemorrhagic Shock Requiring Massive Transfusion.},
  author={James C McMillen and Christy M Lawson and A Shaun Rowe},
  journal={Hospital pharmacy},
  year={2013},
  volume={48 9},
  pages={753-6}
}
OBJECTIVE Recombinant human factor VII activated (rFVIIa) is an adjuvant therapy in patients receiving massive transfusion for hemorrhagic shock. We compared patient characteristics and outcomes to determine futility criteria for the administration of rFVIIa in patients receiving massive transfusion for hemorrhagic shock. METHODS This was a retrospective… CONTINUE READING